1,530
edits
PARTNER A: Difference between revisions
Jump to navigation
Jump to search
→Criticisms
| Line 156: | Line 156: | ||
* Excluded specific groups that may benefit from TAVR, including those with CAD, severe PVD, and LVEF <20%<ref>[http://www.ncbi.nlm.nih.gov/pubmed/21251642 George JC et al. "Transcatheter aortic valve implantation: Lessons from the PARTNER (Placement of Aortic Transcatheter Valves) trial." ''JACC Cardiovascular Interventions.'' 2011;4(1):132-133.]</ref> | * Excluded specific groups that may benefit from TAVR, including those with CAD, severe PVD, and LVEF <20%<ref>[http://www.ncbi.nlm.nih.gov/pubmed/21251642 George JC et al. "Transcatheter aortic valve implantation: Lessons from the PARTNER (Placement of Aortic Transcatheter Valves) trial." ''JACC Cardiovascular Interventions.'' 2011;4(1):132-133.]</ref> | ||
* Significant (4.6%) crossover to surgical AVR in the TAVR group, which may have biased toward noninferiority of TAVR | * Significant (4.6%) crossover to surgical AVR in the TAVR group, which may have biased toward noninferiority of TAVR | ||
* Actual surgical mortality at 30 days was 3% lower than expected by STS score, potentially limiting power to detect superiority of TAVR over | * Actual surgical mortality at 30 days was 3% lower than expected by STS score, potentially limiting power to detect superiority of TAVR over surgical AVR | ||
==Funding== | ==Funding== | ||